Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.39 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4595894 | 1.00 | KMT2A (0.46) | KMT2APTPN1POLBPKMPTPN7 | |
| SCHEMBL43514 | 1.00 | KMT2A (0.46) | KMT2APTPN1POLBPKMPTPN7 | |
| Gamma-Aminobutyric Acid SCHEMBL2770343 | 0.84 | KMT2A (0.41) | KMT2APTPN1POLBPKMPTPN7 | |
| SCHEMBL29747049 | 0.81 | KMT2A (0.43) | KMT2APTPN1POLBPKMPTPN7 | |
| SCHEMBL29747363 | 0.80 | KMT2A (0.46) | KMT2APTPN1POLBPKMPTPN7 | |
| Hydrochloric Acid SCHEMBL9473668 | 0.80 | ALDH1A1 (0.51) | KMT2APOLBL3MBTL1SMN1; SMN2ALOX5 | |
| Hydrochloric Acid SCHEMBL9473673 | 0.80 | ALDH1A1 (0.51) | KMT2APOLBL3MBTL1SMN1; SMN2ALOX5 | |
| SCHEMBL19463110 | 0.80 | KDM4E (0.39) | POLBSMN1; SMN2ALDH1A1KDM4E | |
| SCHEMBL9955771 | 0.78 | MME (0.43) | POLBL3MBTL1ALDH1A1MAPT | |
| SCHEMBL9955768 | 0.78 | MME (0.43) | POLBL3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1405 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | SOCPRA SCIENCES SANTÉ ET HUMAINES S.E.C. (CA) | 2025-07-15 | — | — | US | claimed |
| EP-3912641-B1 | HYDROPHILIC DRUG-LINKER COMPOUNDS | SEAGEN INC (US) | 2024-11-06 | — | — | EP | claimed |
| EP-4274838-B1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LTD (GB) | 2024-09-25 | — | — | EP | claimed |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BICYCLETX LIMITED (GB) | 2024-04-04 | — | — | US | claimed |
| WO-2024030977-A2 | NOVEL MELANOCORTIN ANALOGS | SIGHTSTREAM BIOTHERAPEUTICS, INC. (US) | 2024-02-08 | — | — | WO | claimed |
| CN-117529489-A | Bicyclic peptide ligands specific for NK cells | 拜斯科技术开发有限公司 | 2024-02-06 | — | — | CN | claimed |
| EP-4274838-A2 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | BicycleTx Limited (GB) | 2023-11-15 | — | — | EP | claimed |
| US-20230132738-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | SEAGEN INC (US) | 2023-05-04 | — | — | US | claimed |
| US-20230021419-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | BICYCLETX LIMITED (GB) | 2023-01-26 | — | — | US | claimed |
| US-11510959-B2 | Hydrophilic antibody-drug conjugates | SEAGEN INC. (US) | 2022-11-29 | — | — | US | claimed |
| US-20070027091-A1 | Novel Melanocortin Receptor Agonists | NOVO NORDISK A/S (DK) | 2007-02-01 | — | — | US | claimed |
| WO-2007009894-A2 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2007-01-25 | — | — | WO | claimed |
| WO-2006108818-A2 | TRIMERIC PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2006-10-19 | — | — | WO | claimed |
| EP-1670815-A2 | MELANOCORTIN RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2006-06-21 | — | — | EP | claimed |
| WO-2006048452-A2 | PEPTIDES FOR USE IN TREATING OF OBESITY | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | WO | claimed |
| WO-2006048451-A1 | PEPTIDES FOR USE IN THE TREATMENT OF OBESITY | NOVO NORDISK A/S (DK) | 2006-05-11 | — | — | WO | claimed |
| EP-1625158-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2006-02-15 | — | — | EP | claimed |
| WO-2005030797-A2 | MELANOCORTIN RECEPTOR AGONISTS | NOVO NORDISK A/S (DK) | 2005-04-07 | — | — | WO | claimed |
| WO-2004099246-A2 | PEPTIDES FOR USE IN TREATING OBESITY | NOVO NORDISK A/S (DK) | 2004-11-18 | — | — | WO | claimed |
| US-6566338-B1 | Administering caspase inhibitor for therapy of oral mucositis, gastrointestinal mucositis, bladder mucositis or proctitis resulting from chemotherapy or radiation therapy of cancer in an animal | CYTOVIA, INC. | 2003-05-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11510959-B2 | Hydrophilic antibody-drug conjugates | CD44, FCGR1A, FCGR2A | KMT2A 1371/4885PTPN1 3862/4885POLB 4239/4885 |
| US-20070027091-A1 | Novel Melanocortin Receptor Agonists | MC4R, MC3R, MC5R | KMT2A 3423/4885PTPN1 1041/4885POLB 3655/4885 |
| US-20240108738-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS | PBK, KLRK1, MICA | KMT2A 1977/4885PTPN1 2190/4885POLB 4155/4885 |
| US-20230021419-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR IL-17 | IL17A, IL23R, IL15 | KMT2A 4302/4885PTPN1 1456/4885POLB 4432/4885 |
| US-12358948-B2 | Neurotensinergic agonists and methods of using same preventing or treating pain | VIP, NTSR2, VIPR2 | KMT2A 3715/4885PTPN1 3670/4885POLB 4202/4885 |
| US-20230132738-A1 | HYDROPHILIC ANTIBODY-DRUG CONJUGATES | CD44, FCGR1A, FCGR2A | KMT2A 1371/4885PTPN1 3862/4885POLB 4239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.